NYSE
18.86USD
-0.38 (-1.95%)
We have scored 4 news catalysts on Abrdn Healthcare Opportunities Fund (THQ) over the past 12 months. The biggest single-day move next to one of them came Jul 10, 2026, when THQ closed −0.7%: “Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts”. Coverage across the window leans positive (average ticker sentiment +0.20). Most of the impact sits in sector healthcare and revenue cyclicality.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
781.7M
P/E
—
EPS
—
Beta
0.89
52W range
16.28-20.39
Day range
18.85–19.24
Open
19.16
Prev close
19.24
Volume
86K
Avg volume
181.8K
Dividend
2.15
IPO
2014-07-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Abrdn Healthcare Opportunities Fund — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for THQ: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Managed by Tekla Capital Management LLC, the Tekla Healthcare Opportunities Fund operates as a closed-end, balanced mutual fund. This fund strategically allocates capital across global public equity and debt markets, with a core investment objective of acquiring securities from companies within the healthcare sector. It also invests in various pooled investment vehicles. For its fixed income component, the fund holds corporate debt securities across the full spectrum of credit ratings. Established on April 2, 2014, and domiciled in the United States, its portfolio performance is measured against both the S&P 1500 Healthcare Index and the S&P 500 Index.
